A PHASE 1B STUDY OF BCL-XL DEGRADER DT2216 COMBINED WITH PACLITAXEL IN RECURRENT PLATINUM-RESISTANT OVARIAN CANCER

$1,598,801FY2025Defense Health AgencyDOD

Dana-Farber Cancer Institute, Inc.

Investigators